NCT04874428View on ClinicalTrials.gov

Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Liver Cirrhosis
Interventions
DRUG

Rivaroxaban 10 mg Oral Tablet

Administration of one single dose of rivaroxaban (10 mg) in tablet form.

DRUG

Apixaban 2.5 mg Oral Tablet

Administration of one single dose of apixaban (2.5 mg) in tablet form.

Trial Locations (1)

3010

RECRUITING

Department of Visceral Surgery and Medicine, University Hospital Inselspital, Berne, Bern

All Listed Sponsors
collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04874428 - Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | Biotech Hunter | Biotech Hunter